drugset

drugset / Trial / NCT06581159

Study of HS135 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

NCT06581159 ↗

Phase 1 Terminated 4 enrolled 35Pharma Inc

RandomizedSequentialDouble-blindTreatment

Summary

A Study of HS135 for the Treatment of in Obese Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Timeline

Start: 2025-01-23
Primary completion: 2025-07-29
Completion: 2025-07-29

Outcome

Outcome not reported

Stopped: “Sponsor's Decision”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HS135	Unknown	—	Subcutaneous

Indications